Expert oncologists discuss the hormone receptor–positive (HR+) breast cancer treatment landscape and their suggested approaches to treating patients in both the early and metastatic disease settings.
January 16th 2023
Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.
Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.
January 23rd 2023
Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.
Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.
January 30th 2023
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.
Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.
February 6th 2023
Experts in oncology consider when surgery is appropriate for patients with breast cancer.
A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.
February 13th 2023
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.